Drug
Alirocumab clinical trials
Also written Praluent, REGN727 and SAR236553.
Keep track of what changes. Save the alirocumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
77 studies that test it; most in 2012 (14); 1 more planned to start later
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 7 |
| 2012 | 14 |
| 2013 | 6 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 7 |
| 2017 | 8 |
| 2018 | 8 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 48 · Other 30
Sanofi (30) · Regeneron Pharmaceuticals (16) · Duke University (2) · University Medical Centre Ljubljana (2) · Kobe University (2) · Chang Gung Memorial Hospital (1) · University of California, San Francisco (1) · Stanford University (1)
Often tested with
Tested in the same studies.
Ezetimibe (5) · Atorvastatin (4) · Evolocumab (3) · Rosuvastatin (3) · Simvastatin (3) · Cholestyramine Resin (3) · Niacin (3) · Fenofibrate (3)
Related medicines
As reviewed, each with the page that says it.
- One of PCSK9 Inhibitors source
Studies
Open first, then newest update. How each study uses alirocumab is read from its arms, and is right about nine times in ten.
Testing it · 78
- TOP 2301: Neoadjuvant Chemo for NSCLCRecruitingPhase 2Duke UniversityNCT06385262Written as Alirocumab
- Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy DrinkersRecruitingPhase 1National Institute on Alcohol Abuse and Alcoholism (NIAAA)NCT04781322Written as Alirocumab
- Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary PreventionRecruitingPhase 4University Medical Centre LjubljanaNCT07581808Written as Alirocumab
- Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid PlaqueNot yet recruitingPhase 3Middle East North Africa Stroke and Interventional Neurotherapies OrganizationNCT07586540Written as Alirocumab
- Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium InfarctionRecruitingPhase 4Shanghai Tong Ren HospitalNCT05292404Written as alirocumab
- Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)Not yet recruitingNot applicableJena University HospitalNCT05587621Written as statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran
- Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS)Not yet recruitingPhase 3The First Affiliated Hospital with Nanjing Medical UniversityNCT06080256Written as Alirocumab
- The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid ProfileNot yet recruitingPhase 4Sun U. KwonNCT06083961Written as Alirocumab
- Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant RecipientsRecruitingPhase 4Institute for Clinical and Experimental MedicineNCT04193306Written as Alirocumab
- A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have HypercholesterolemiaActive, not recruitingPhase 2Regeneron PharmaceuticalsNCT07477704Written as Alirocumab
- Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)CompletedPhase 3University of California, San FranciscoNCT03207945Written as Alirocumab
- Cardiac Allograft Vasculopathy Inhibition With AlirocumabCompletedPhase 2Stanford UniversityNCT03537742Written as alirocumab
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell LungActive, not recruitingPhase 2Duke UniversityNCT05553834Written as Alirocumab and Cemiplimab
- Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial AtherosclerosisActive, not recruitingPhase 2Chang Gung Memorial HospitalNCT05001984Written as Alirocumab
- Alirocumab in Patients with SepsisCompletedPhase 1Jonathan SevranskyNCT05469347Written as Alirocumab
- Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 InhibitorsCompletedPhase 1Food and Drug Administration (FDA)NCT04189484Written as Alirocumab
- A Trial of Alirocumab and Plaque Regression in Peripheral Arterial DiseaseCompletedPhase 4University of VirginiaNCT02959047Written as Alirocumab
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial HypercholesterolemiaCompletedPhase 3SanofiNCT03510884Written as Alirocumab SAR236553 (REGN727)
- Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 DiabetesCompletedPhase 3Nantes University HospitalNCT03344692Written as Alirocumab
- Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic SyndromeTerminatedPhase 2Gloria VegaNCT03004001Written as Alirocumab
See all 78 studies that test alirocumab →
Given in every arm · 1 — alirocumab is usual care beside what is tested
As the comparator · 2 — what is tested is compared with alirocumab
- Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD PatientsCompletedPhase 3LIB Therapeutics LLCNCT04790513Written as alirocumab
- PCSK9 Inhibition in Patients With Symptomatic Intracranial AtherosclerosisTerminatedEarly Phase 1University of UtahNCT03507374Written as Alirocumab
Codes
What other systems call alirocumab · ClinicalTrials.gg INT006016
- MeSH (NLM) C571059alirocumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) PP0SHH6V16ALIROCUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1659152Confirmed FDA, Wikidata
- Wikidata Q4726914alirocumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174849AlirocumabOne source FDA
- DrugBank DB09302One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C571059 | alirocumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | PP0SHH6V16 | ALIROCUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1659152 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4726914 | alirocumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174849 | Alirocumab | One source FDA |
| DrugBank | DB09302 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.